PRTN3 and rheumatoid arthritis: Multiple studies have demonstrated that elevated ACPA levels are present in preclinical RA, and the presence of ACPA is highly specific for predicting the future development of RA, with a specificity of 85–95% and a sensitivity of 67% [66,67,68].